Dengue & Thrombocytopenia

Introduction

Dengue is one of the most widespread mosquito-borne illnesses in the world. This guide focuses on the part of dengue that matters most on the ward and in the lab: the platelet story. We will also cover the basics — what dengue is, how it presents, how it is diagnosed, and how it is managed in 2026.

Dengue is a systemic infection. It can run silently in the background or land a patient in intensive care. The reason for that wide range sits in the interaction between four viral serotypes and the immune memory of the person they infect.

Global Burden

Dengue is rising faster than any other communicable disease. WHO logged over 14.3 million cases and more than 10,500 deaths from 112 countries in 2024, the worst year on record [1,7]. Roughly four billion people now live in areas at risk. Urban density, international travel, and a warming climate that extends mosquito habitats are the main drivers. Most cases occur in Asia, with Latin America and Africa carrying the rest.

Dengue Virus: Serotypes and Antigenic Diversity

Dengue virus is a single-stranded RNA virus in the Flaviviridae family. Four serotypes — DENV-1, DENV-2, DENV-3, and DENV-4 — are well established. A possible fifth serotype, DENV-5, has been described but not independently confirmed and is not part of current clinical thinking.

The serotypes share most of their genetic material but differ in their surface proteins. That small difference matters. Surviving DENV-1 gives long-lasting protection against DENV-1, but only short-term cross-protection against the other three. When that cross-protection fades, a second infection with a different serotype can be more dangerous than the first. The reason is a phenomenon called antibody-dependent enhancement, which we will return to.

How the Virus Enters Cells

The dengue virus targets dendritic cells, macrophages, and the cells lining blood vessels (endothelial cells). After a mosquito bite, the virus binds to a receptor on a host cell, is taken in by endocytosis, fuses with the inner vesicle in an acidic environment, and releases its RNA into the cytoplasm. The host cell's own machinery is hijacked to make new viral proteins and copies of the RNA. New viruses assemble at the endoplasmic reticulum, mature through the Golgi apparatus, and are released to infect new cells [2,8]. For clinical purposes, the key point is this: the virus infects immune cells and endothelial cells, and that is what links the infection to immune dysregulation and plasma leakage.

Dengue Pathogenesis

Primary Infection

The first time a person meets dengue, the innate immune system (interferons, natural killer cells) limits viral replication while B and T cells mount a serotype-specific response over 5–7 days. Most primary infections clear within a week or two. Symptoms like fever, headache, muscle pain, rash are largely the result of the immune response itself, not direct viral damage.

Secondary Infection and Antibody-Dependent Enhancement (ADE)

Years after a primary infection, antibodies from that first encounter still circulate. If the person is now infected with a different serotype, those antibodies bind to the new virus but do not neutralize it. The antibody-virus complex enters immune cells through Fc receptors more efficiently than the virus alone would [9]. The result is a higher viral load, a stronger inflammatory response, and a real risk of plasma leakage.

Beyond ADE, modern pathogenesis also highlights the role of aberrant cross-reactive memory T-cells. During a secondary infection, memory T-cells from the primary infection recognize the new serotype but mount a suboptimal, highly inflammatory response. This 'cytokine storm' directly contributes to endothelial cell permeability and the resulting plasma leakage [11].

This explains why severe dengue is more common in secondary infections, particularly in regions where multiple serotypes circulate.

The Thrombocytopenia Mechanism

Platelets fall in dengue for several reasons working at once.

Reduced production. The virus can infect hematopoietic progenitor cells and bone marrow stromal cells, suppressing the maturation and release of new platelets.

Increased destruction. In the bloodstream, dengue virus particles can bind directly to platelets and mark them for removal by macrophages in the spleen and liver. Inflammatory cytokines released during infection activate endothelial cells and leukocytes, which in turn destroy platelets.

Consumption at damaged endothelium. Vascular injury during severe dengue activates the clotting system locally, consuming platelets.

Possible role of ADE. Pre-existing cross-reactive antibodies may target platelets that display dengue antigens, adding to the destruction.

The clinical consequence is a platelet count that typically drops from day 3, hits its lowest point between day 4 and day 7, and recovers over the following week.

The Three Clinical Phases of Dengue

Dengue is best understood as a three-phase illness. Recognizing the phase changes everything about how a patient is monitored.

Febrile phase (days 1–3): Sudden high fever (often 39–40°C), severe headache, retro-orbital pain, muscle and joint pain (the classic "breakbone" symptoms), and sometimes a flushed rash. NS1 antigen and RT-PCR are most useful here.

Critical phase (days 3–7, around the time fever breaks): This is the dangerous window. Plasma can leak out of blood vessels, causing falling blood pressure, rising hematocrit, and pleural effusion or ascites in severe cases. Platelet counts hit their lowest point. Most cases of severe dengue declare themselves here.

Recovery phase (day 7 onwards): Leaked fluid is reabsorbed, platelets rise, appetite returns. A second rash, sometimes described as "isles of white in a sea of red", can appear.

Signs and Symptoms

Classic Dengue Fever

After 4–10 days of incubation, the typical presentation includes:

• Sudden high fever (40°C or higher)
• Severe headache, often with pain behind the eyes
• Muscle and joint pain
• Nausea and vomiting
• Rash, often appearing on day 3–5 as red flushing on the face and trunk

Warning Signs

WHO's "warning signs" are a specific list because their presence moves a patient from outpatient monitoring to admission [1,10]:

• Severe abdominal pain
• Persistent vomiting (three or more times in 24 hours)
• Clinical fluid accumulation (pleural effusion, ascites)
• Mucosal bleeding (nose, gums, gastrointestinal)
• Lethargy or restlessness
• Liver enlargement greater than 2 cm
• Rising hematocrit with rapidly falling platelet count

Severe Dengue

Severe dengue is the current WHO category that replaces the older DHF/DSS terms. It is defined by at least one of:

• Severe plasma leakage leading to shock or fluid accumulation with respiratory distress
• Severe bleeding
• Severe organ involvement (liver, heart, brain, kidneys)

Complications

Severe Plasma Leakage and Shock

The defining complication. Fluid escapes blood vessels into the pleural space, the peritoneum, and tissues. Effective circulating volume falls. If untreated, shock follows: rapid weak pulse, cold clammy skin, narrowing pulse pressure, and eventually organ failure.

Bleeding

Most dengue bleeding is mild (petechiae, gum bleeding). Major bleeding like gastrointestinal hemorrhage or intracranial bleeding is rare but life-threatening and usually happens in the setting of prolonged shock or coagulopathy, not isolated thrombocytopenia.

Organ Involvement

Hepatitis (raised transaminases, sometimes jaundice), myocarditis, encephalitis, and acute kidney injury can all occur. Severe liver involvement is a poor prognostic sign.

Hemophagocytic Lymphohistiocytosis (HLH)

A rare hyperinflammatory syndrome where overactive macrophages engulf blood cells, causing cytopenias and multiorgan damage. It is more often reported in children with severe dengue and requires immunosuppressive treatment.

Laboratory Diagnosis

Diagnosis combines clinical suspicion, travel or residence history, and laboratory tests.

Tests That Detect the Virus

• RT-PCR: The gold standard in the first 5–7 days of illness. Detects viral RNA directly and confirms an active infection.
• NS1 antigen: A viral protein detectable primarily from day 1 to day 5. Its clinical sensitivity drops sharply after day 5 as the patient's emerging antibodies clear the antigen, meaning late testing often yields false negatives [13]. Available as a rapid point-of-care test.

Tests That Detect the Immune Response

• IgM ELISA: Becomes positive around day 4–5 and persists for 2–3 months. Suggests recent or current infection.
• IgG ELISA: Rises later and persists for years. In a secondary infection, IgG spikes rapidly and massively within the first few days, while IgM levels are often distinctly lower or even undetectable. A towering IgG with a low/absent IgM early in the illness is the classic serological signature of a high-risk secondary infection [13].

Tests That Track Severity

• Complete blood count (CBC): Watch the platelet count and hematocrit. Falling platelets plus rising hematocrit is the early signal of plasma leakage.
• Liver function tests: Mild elevation is common; sharp rises suggest severe disease.
• Coagulation studies: Used when bleeding is significant.

Differential Diagnosis

Many tropical fevers look like dengue in the first 48 hours. A short comparison helps separate the most common confusion — dengue, chikungunya, and Zika, all spread by the same mosquitoes:

Also consider leptospirosis, typhoid, malaria, rickettsial infections, and influenza, especially in returning travelers.

Dengue Management and Treatment

There is no specific antiviral drug for dengue. Care is supportive and tailored to the clinical phase.

Mild Dengue Without Warning Signs

• Rest and hydration. Oral rehydration is the foundation. Encourage water, oral rehydration solution, and fruit juices.
• Pain and fever relief. Use paracetamol (acetaminophen). Avoid aspirin and ibuprofen as they increase the risk of bleeding.
• Monitoring. Daily review while fever continues, with a clear plan to return if warning signs appear.

Dengue With Warning Signs

Admit for close monitoring. Start intravenous isotonic crystalloid at a controlled rate, monitor vital signs, urine output, hematocrit, and platelet count. The aim is to support the patient through the critical phase without overloading them with fluid.
Clinicians must be hyper-vigilant regarding iatrogenic fluid overload, which has become a leading cause of mortality in severe dengue. Intravenous fluids must be dynamically titrated to the patient's hematocrit and hemodynamic status, and stepped down or discontinued immediately once the critical phase passes and fluid reabsorption begins [14].

Severe Dengue

Manage in a high-dependency or intensive care setting. Cautious crystalloid resuscitation, colloid for refractory shock, blood products for major bleeding, and treatment of organ failure as it arises [1].

Platelet Transfusion in Dengue — Current Thinking

This is where dengue practice has changed and where many older sources are wrong. The 2025 AABB and ICTMG international guidelines make a clear recommendation: in dengue patients with thrombocytopenia but without major bleeding, prophylactic platelet transfusion is not recommended [3]. The recommendation rests on strong evidence, including a 2017 multicenter randomized trial that found prophylactic platelet transfusion did not prevent bleeding and was associated with more adverse events [4].

In practice:

• Active major bleeding → transfuse, regardless of platelet count.
• Invasive procedure planned → maintain platelets above the threshold appropriate to the procedure.
• Low platelet count alone → monitor, do not transfuse.

A platelet count of 15,000/µL in a stable dengue patient looks alarming, but the evidence says do not transfuse on the number alone.

Prevention and Vaccines

Mosquito Control and Personal Protection

• Eliminate standing water around the home: tires, flower pots, gutters, water containers.
• Use insect repellents containing DEET, picaridin, IR3535, or oil of lemon eucalyptus.
• Wear long sleeves and trousers during peak biting hours (dawn and dusk for Aedes).
• Use bed nets and window screens where mosquitoes get indoors.

Vaccines

Two dengue vaccines have been licensed. The landscape changed substantially between 2023 and 2025.

Qdenga (TAK-003), developed by Takeda, is a live attenuated tetravalent vaccine built on a DENV-2 backbone. In September 2023, the WHO Strategic Advisory Group of Experts (SAGE) recommended its use in children aged 6–16 in settings with high dengue transmission. The schedule is two doses given three months apart. Unlike the older vaccine, Qdenga can be given to people who have not had dengue before [6].

Dengvaxia (CYD-TDV), made by Sanofi, was the first dengue vaccine licensed (2015). Its use was limited because seronegative recipients had an increased risk of severe dengue after vaccination. Pre-vaccination serological testing was required. Sanofi announced discontinuation of production in 2024, and remaining stock expires in August 2026 [5].

Research on next-generation vaccines (including the NIH's TV003/TV005 and mRNA candidates) is active. Wolbachia-based mosquito deployments have transitioned from experimental research to a primary global public health strategy. By introducing Wolbachia bacteria into Aedes aegypti populations which drastically reduces their ability to transmit the virus, cities have recorded up to an 80% to 90% reduction in local dengue incidence, making it one of the most successful vector control interventions to date [15].

Frequently Asked Questions (FAQs)

Why do platelets drop in dengue?

Platelets fall in dengue for two reasons working at the same time. The virus reaches the bone marrow and slows down the production of new platelets. At the same time, in the bloodstream, platelets are activated, destroyed by immune cells, and consumed at sites of vessel injury. The lowest platelet counts typically appear between days 4 and 7 of illness, around the same time the fever starts to fall.

Do dengue patients always need a platelet transfusion when their count is low?

No. Current 2025 international guidelines (AABB and ICTMG) recommend against prophylactic platelet transfusion in dengue patients who have a low count but are not bleeding seriously. Large trials, including a 2017 multicenter study in Asia, showed transfusion does not prevent bleeding and can cause harm. Platelets are reserved for patients with major bleeding or those needing invasive procedures.

What is the "critical phase" in dengue and why does it matter?

After the fever breaks (usually day 3 to 7), dengue patients enter a 24 to 48 hour window called the critical phase. This is when plasma can leak out of blood vessels, dropping blood pressure and causing shock. Patients can feel better just before they get much worse. Health workers monitor pulse, blood pressure, hematocrit, and platelet count closely during this phase.

Is there a vaccine for dengue?

Yes. Two vaccines exist. Qdenga (TAK-003), made by Takeda, is recommended by the WHO for children aged 6–16 in areas with high dengue transmission and is given as two doses three months apart. It can be given whether or not the person has had dengue before. Dengvaxia (CYD-TDV), the older vaccine, is being phased out as its manufacturer stopped production in 2024 and remaining stock expires in August 2026.

How is dengue different from chikungunya and Zika?

All three are spread by the same Aedes mosquitoes and can cause fever and rash. Chikungunya causes severe and often long-lasting joint pain. Zika usually causes a milder illness but is dangerous in pregnancy because it can harm the developing baby. Dengue is the most likely of the three to cause low platelets, plasma leakage, and shock. Laboratory testing is often needed to tell them apart.

Can dengue spread from person to person?

Dengue does not spread by coughing, touching, or sharing food. It needs a mosquito to carry the virus from one person to another. The mosquito bites an infected person, the virus multiplies inside the mosquito for about a week, and then the mosquito can pass it on at the next bite. Rare exceptions include mother-to-baby transmission during pregnancy or birth, transfusion of infected blood, and organ transplant.

Are dengue and yellow fever the same?

No. Both are mosquito-borne flavivirus infections, but they differ in geography, severity, and prevention.

Glossary of Related Medical Terms

• Aedes aegypti / Aedes albopictus — The two mosquito species that spread dengue. Both bite during the day. Ae. aegypti is the main one in cities.
• Antibody-dependent enhancement (ADE) — When antibodies from a past infection help, rather than block, a new virus enter immune cells. Explains why a second dengue infection (with a different serotype) is often worse than the first.
• Critical phase — The 24–48 hour window around defervescence (when fever breaks) when plasma leakage and shock are most likely.
• Defervescence — The point when fever resolves. In dengue, paradoxically, this is when patients can get sicker, not better.
• Dengue hemorrhagic fever (DHF) — Older WHO term for severe dengue with plasma leakage and bleeding. Still seen in older literature.
• Dengue shock syndrome (DSS) — Older term for the shock state that can follow DHF when plasma leakage is severe.
• Hematocrit — The percentage of blood made up of red blood cells. In dengue, a rising hematocrit signals plasma leaking out of vessels.
• NS1 antigen — A dengue viral protein detectable in blood from day 1 of fever. Used in rapid diagnostic tests.
• Plasma leakage — Fluid escaping from blood vessels into surrounding tissues. The defining feature of severe dengue.
• RT-PCR — A test that detects the genetic material of the virus directly. The best test in the first week of illness.
• Serotype — A version of a virus distinguished by its surface proteins. Dengue has four (DENV-1 to DENV-4).
• Severe dengue — The current WHO category that replaces DHF/DSS. Defined by severe plasma leakage, severe bleeding, or severe organ involvement.
• Thrombocytopenia — A platelet count below 150,000/µL. In dengue, the count typically drops between days 3 and 7.
• Tourniquet test — A bedside test where a blood pressure cuff is inflated for 5 minutes. More than 10 petechiae per square inch suggests dengue.
• Warning signs — A specific WHO list (abdominal pain, persistent vomiting, mucosal bleeding, lethargy, liver enlargement, fluid accumulation, rising hematocrit with falling platelets) that flags patients at risk of progressing to severe dengue.

Disclaimer: This article is intended for educational and informational purposes only. It is not intended to be a substitute for informed professional medical advice, diagnosis, or treatment. While the information presented here is derived from credible medical sources and is believed to be accurate and up-to-date, it is not guaranteed to be complete or error-free. See additional information.

References

1. World Health Organization. (2025, July 10). New WHO guidelines for clinical management of arboviral diseases: Dengue, chikungunya, Zika and yellow fever. WHO News. https://www.who.int/news/item/10-07-2025-new-who-guidelines-for-clinical-management-of-arboviral-diseases--dengue--chikungunya--zika-and-yellow-fever
2. World Health Organization. (2009). Dengue: Guidelines for diagnosis, treatment, prevention and control (New ed.). WHO Press.
3. Metcalf, R. A., Nahirniak, S., Guyatt, G., Bathla, A., White, S. K., Al-Riyami, A. Z., Jug, R. C., La Rocca, U., Callum, J. L., Cohn, C. S., DeAnda, A., DeSimone, R. A., Dubon, A., Estcourt, L. J., Filipescu, D. C., Fung, M. K., Goel, R., Hess, A. S., Hume, H. A., Kaufman, R. M., … Stanworth, S. J. (2025). Platelet Transfusion: 2025 AABB and ICTMG International Clinical Practice Guidelines. JAMA, 334(7), 606–617. https://doi.org/10.1001/jama.2025.7529
4. Lye, D. C., Archuleta, S., Syed-Omar, S. F., Low, J. G., Oh, H. M., Wei, Y., Fisher, D., Ponnampalavanar, S. S. L., Wijaya, L., Lee, L. K., Ooi, E. E., Kamarulzaman, A., Lum, L. C., Tambyah, P. A., & Leo, Y. S. (2017). Prophylactic platelet transfusion plus supportive care versus supportive care alone in adults with dengue and thrombocytopenia: a multicentre, open-label, randomised, superiority trial. Lancet (London, England), 389(10079), 1611–1618. https://doi.org/10.1016/S0140-6736(17)30269-6
5. Biswal, S., Reynales, H., Saez-Llorens, X., Lopez, P., Borja-Tabora, C., Kosalaraksa, P., Sirivichayakul, C., Watanaveeradej, V., Rivera, L., Espinoza, F., Fernando, L., Dietze, R., Luz, K., Venâncio da Cunha, R., Jimeno, J., López-Medina, E., Borkowski, A., Brose, M., Rauscher, M., LeFevre, I., … TIDES Study Group (2019). Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents. The New England journal of medicine, 381(21), 2009–2019. https://doi.org/10.1056/NEJMoa1903869
6. Tricou, V., Yu, D., Reynales, H., Biswal, S., Saez-Llorens, X., Sirivichayakul, C., Lopez, P., Borja-Tabora, C., Bravo, L., Kosalaraksa, P., Vargas, L. M., Alera, M. T., Rivera, L., Watanaveeradej, V., Dietze, R., Fernando, L., Wickramasinghe, V. P., Moreira, E. D., Jr, Fernando, A. D., Gunasekera, D., … Wallace, D. (2024). Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Global health, 12(2), e257–e270. https://doi.org/10.1016/S2214-109X(23)00522-3
7. World Health Organization. (2025). Dengue and severe dengue: Fact sheet. https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue
8. Rodenhuis-Zybert, I. A., Wilschut, J., & Smit, J. M. (2010). Dengue virus life cycle: viral and host factors modulating infectivity. Cellular and molecular life sciences : CMLS, 67(16), 2773–2786. https://doi.org/10.1007/s00018-010-0357-z
9. Halstead S. B. (2014). Dengue Antibody-Dependent Enhancement: Knowns and Unknowns. Microbiology spectrum, 2(6), 10.1128/microbiolspec.AID-0022-2014. https://doi.org/10.1128/microbiolspec.AID-0022-2014
10. Centers for Disease Control and Prevention. (2025). Guidelines for classifying dengue. https://www.cdc.gov/dengue/hcp/clinical-signs/guidelines.html
11. Rothman A. L. (2011). Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nature reviews. Immunology, 11(8), 532–543. https://doi.org/10.1038/nri3014
12. Simmons, C. P., Farrar, J. J., Nguyen, vV., & Wills, B. (2012). Dengue. The New England journal of medicine, 366(15), 1423–1432. https://doi.org/10.1056/NEJMra1110265
13. Muller, D. A., Depelsenaire, A. C., & Young, P. R. (2017). Clinical and Laboratory Diagnosis of Dengue Virus Infection. The Journal of infectious diseases, 215(suppl_2), S89–S95. https://doi.org/10.1093/infdis/jiw649
14. World Health Organization. (2012). Handbook for clinical management of dengue. WHO Press.
15. Utarini, A., Indriani, C., Ahmad, R. A., Tantowijoyo, W., Arguni, E., Ansari, M. R., Supriyati, E., Wardana, D. S., Meitika, Y., Ernesia, I., Nurhayati, I., Prabowo, E., Andari, B., Green, B. R., Hodgson, L., Cutcher, Z., Rancès, E., Ryan, P. A., O'Neill, S. L., Dufault, S. M., … AWED Study Group (2021). Efficacy of Wolbachia-Infected Mosquito Deployments for the Control of Dengue. The New England journal of medicine, 384(23), 2177–2186. https://doi.org/10.1056/NEJMoa2030243